patients beginning an in vitro fertilization ( ivf ) treatment cycle were prospectively randomized in double-blind fashion to receive either follicle-stimulating hormone ( fsh ) ( metrodin , serono laboratories , inc. , randolph , ma ) ( n = 50 ) or human menopausal gonadotropin ( hmg ) ( pergonal , serono ) ( n = 48 ) in combination with clomephene citrate ( cc ) ( serophene , serono ) .
C0025326
human menopausal gonadotropin
C0700188
pergonal